Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06449677 · ClinicalTrials.gov registry record · Phase 3

Bionic Pancreas in CFRD

A Phase 3 study of Cystic Fibrosis-related Diabetes, sponsored by Jaeb Center for Health Research.

Recruiting
Registry status
Phase 3
Development phase
150
Enrollment target
16
Study locations

NCT06449677: Recruiting Phase 3 study of Cystic Fibrosis-related Diabetes, sponsored by Jaeb Center for Health Research.

NCT06449677 is a Phase 3 study of Cystic Fibrosis-related Diabetes that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 150 participants, above the 93-participant average among 10 other Cystic Fibrosis-related Diabetes trials with a reported enrollment target (61% higher). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06449677, a Phase 3 study of Cystic Fibrosis-related Diabetes, is actively recruiting participants, sponsored by Jaeb Center for Health Research.

RECRUITING
Registry status
Phase 3
Development phase
150 participants
Enrollment target
16
Study locations

Study Summary

This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.

Primary Outcome

CGM-measured time in target range of 70-180 mg/dL (TIR)

Conditions Studied

Cystic Fibrosis-related Diabetes

Interventions

  • DEVICE iLet Bionic Pancreas System (BP)
  • DEVICE Usual Care (UC)

Study Locations (16)

Texas

  • UT Southwestern Medical Center - Dallas
  • Baylor College of Medicine - Houston
  • University of Texas Health San Antonio - San Antonio

Colorado

  • University of Colorado-Barbara Davis Center for Diabetes - Aurora

Connecticut

  • Yale University School of Medicine - New Haven

Georgia

  • Emory University - Atlanta

Indiana

  • Indiana University School of Medicine - Indianapolis

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-09-24
Est. Completion 2027-03-30
Phase Phase 3
Jaeb Center for Health Research

119 total trials

What NCT06449677 shows while recruiting

NCT06449677 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 10 other Cystic Fibrosis-related Diabetes trials with a reported enrollment target (61% higher).

The record links to 1 condition, with Cystic Fibrosis-related Diabetes appearing as the primary indexed condition, and to 2 interventions - of which iLet Bionic Pancreas System (BP) is the first listed.

NCT06449677 lists 16 locations in 14 states (Texas, Colorado, Connecticut).

Frequently Asked Questions

What is clinical trial NCT06449677 about?

NCT06449677 is a clinical study titled "Bionic Pancreas in CFRD". This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week s...

What is the current status of trial NCT06449677?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-09-24. Estimated completion is 2027-03-30.

What conditions does trial NCT06449677 study?

This clinical trial studies the following conditions: Cystic Fibrosis-related Diabetes.

What interventions are being tested in trial NCT06449677?

The interventions under investigation include: iLet Bionic Pancreas System (BP) (DEVICE), Usual Care (UC) (DEVICE).

Who is sponsoring clinical trial NCT06449677?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06449677 being conducted?

This trial has 16 study locations across Colorado, Connecticut, Georgia, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis-related Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06449677's enrollment target sits among peer trials

150 3rd of 10 higher than 8 of 10 other Cystic Fibrosis-related Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis-related Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06449677

Source: ClinicalTrials.gov NCT06449677, the US trial registry maintained by the National Library of Medicine. NCT06449677 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.